A20单倍剂量不足(HA20)的临床表型与实验室标志物:意大利两中心病例系列
该研究回顾性分析两个意大利中心6个家系17例TNFAIP3杂合变异(ACMG 4-5类)患者,描述HA20临床异质性。口腔阿弗他(88%)、反复发热(53%)、胃肠道炎症(53%)常见;5岁前起病与终生神经精神症状高发相关(p=0.004)。活动期患者1型干扰素特征(IS)水平更高(p<0.01)。
要点
- HA20临床异质性显著,家族内及家族间表现多样。
- 5岁前起病与终生神经精神症状高发相关(p=0.004)。
- 1型干扰素特征(IS)或为HA20疾病活动潜在生物标志物。
核心结论
- HA20临床异质性显著,家族内及家族间表现多样。
- 5岁前起病与终生神经精神症状高发相关(p=0.004)。
- 1型干扰素特征(IS)可能作为HA20疾病活动性的潜在生物标志物。
研究设计与样本
- 回顾性收集两个意大利中心6个家系17例TNFAIP3杂合变异(ACMG 4-5类)患者的临床与实验室数据。
- 连续变量以中位数(IQR)表示,起病年龄用Kruskal-Wallis检验,组间比较用Wilcoxon检验或Fisher精确检验。
主要发现
- 临床表现包括口腔阿弗他(88%)、反复发热(53%)、胃肠道炎症(53%)、自身免疫(47%)、生殖器溃疡(47%)、神经精神症状(41%)、关节炎/腱鞘炎(18%)和皮肤炎症(12%)。
- 5岁前起病与终生神经精神症状较高患病率相关(p=0.004),关节炎在较晚起病患者中更常见。
- 起病年龄中位数随临床表现类型不同而显著差异(p<0.001)。
- 活动期患者IS水平更高(p<0.01)。
关键数值与推荐
- TNFAIP3变异按ACMG分类为4-5类。
- 5岁前起病与终生神经精神症状相关(p=0.004)。
- 活动期患者IS水平更高(p<0.01)。
临床怎么用
- 对HA20患者应关注起病年龄,5岁前起病者需警惕终生神经精神症状。
- 1型干扰素特征(IS)或可用于评估HA20疾病活动性。
- HA20临床表现高度异质,需结合家族史与基因检测综合诊断。
局限性
- 回顾性研究设计。
- 样本量较小(17例来自6个家系)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Haploinsufficiency of A20 (HA20) is a monogenic disease caused by heterozygous TNFAIP3 variants. Despite the marked clinical variability, no genotype-phenotype correlation or validated laboratory biomarkers have been identified so far. Neurobehavioural abnormalities have been reported in murine models, but their prevalence in humans remains unclear. OBJECTIVES: To describe a cohort of patients with HA20 from two centres, evaluating age-related clinical variability; to assess the prevalence of neuropsychiatric symptoms; to explore the inflammatory profile of the patients, including interferon (IFN)-γ-inducible chemokines (CXCL9/10) and type 1 IFN signature (IS), as well as the therapies administered. METHODS: Clinical and laboratory data of 17 subjects from six families heterozygous for TNFAIP3 variants (American College of Medical Genetics and Genomics class 4-5) were retrospectively collected. Disease activity, treatments, CXCL9/10 and IS levels were collected. Continuous variables were expressed as medians (IQR). Age at onset was compared using the Kruskal-Wallis test, and groups were compared through the Wilcoxon test or Fisher's exact test. RESULTS: Clinical manifestations included oral aphthosis (88%), recurrent fever (53%), gastrointestinal inflammation (53%), autoimmunity (47%), genital ulcers (47%), neuropsychiatric symptoms (41%), arthritis/tenosynovitis (18%) and skin inflammation (12%). Disease onset before 5 years of age was associated with a higher prevalence of neuropsychiatric symptoms during lifetime (p=0.004), whereas arthritis was more common in patients with later onset. The median age at onset differed significantly according to the type of clinical manifestation (p<0.001). Higher IS levels were found in patients with active disease (p<0.01). CONCLUSIONS: HA20 shows marked clinical heterogeneity both between and within families. Clinical manifestations appear age-related and early disease onset was associated with increased neuropsychiatric involvement lifetime. Finally, type 1 IS may represent a potential biomarker of disease activity in HA20.
引用
- De Nardi L, Federici S, De Martino E, et al. Clinical phenotype and laboratory markers in patients affected by haploinsufficiency of A20 (HA20): a case series from two Italian centres. RMD Open. 2026. PMID: 42128528. doi:10.1136/rmdopen-2026-006763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。